Cargando…

Causes and factors related to dopamine agonist withdrawal in Parkinson′s disease

BACKGROUND: Although dopamine agonists (DAs) are useful in Parkinson′s disease (PD), they are not frequently used in elderly patients due to adverse effects. However, there is a lack of evidence because few elderly PD patients are enrolled in clinical trials. AIMS OF THE STUDY: The aims of this stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castro, Ester Suárez, Santos‐García, Diego, de Deus Fonticoba, Teresa, Expósito Ruíz, Irene, Tuñas Gesto, Cintia, Arribí, Mercedes Macías
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864043/ https://www.ncbi.nlm.nih.gov/pubmed/27247848 http://dx.doi.org/10.1002/brb3.453

Ejemplares similares

Irreversible extreme freezing of gait after dopamine agonist withdrawal
por: Salari, Mehri, et al.
Publicado: (2021)

Intracerebral Varicella Zoster Virus Vasculopathy in a Patient with Systemic Lupus Erythematosus and Imaging-Clinical Discordance
por: Vázquez-Friol, María del Carmen, et al.
Publicado: (2022)

The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)

5-2-1 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson's Treatment
por: Santos-García, D., et al.
Publicado: (2020)

Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review
por: Garcia, Xiomara, et al.
Publicado: (2022)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
por: Reichmann, Heinz
Publicado: (2009)

The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis
por: Zou, Yunzhi, et al.
Publicado: (2021)

Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects?
por: Schwarzschild, Michael A.
Publicado: (2017)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
por: Frazer, Monica, et al.
Publicado: (2022)

The Convergence of Dopamine and α-Synuclein: Implications for Parkinson’s Disease
por: Mor, Danielle E, et al.
Publicado: (2018)

High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
por: Reynolds, Gavin P
Publicado: (2021)

Influence of Selective Dopamine Agonist Ropinirole on Conditioned Place Preference and Somatic Signs of Morphine Withdrawal in Rats
por: Shahzadi, Andleeb, et al.
Publicado: (2022)

Withdrawing may be preferable to withholding
por: Vincent, Jean-Louis
Publicado: (2005)

Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
por: Zhang, Jinglin, et al.
Publicado: (2016)

Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020)

Dopamine Agonist-Associated Hiccup in Parkinson’s Disease: A Case Report
por: EMEKLİ, Ahmed Serkan, et al.
Publicado: (2019)

Withdrawal of cerivastatin from the world market
por: Furberg, Curt D, et al.
Publicado: (2001)

Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson’s disease
por: Arbouw, Maurits E. L., et al.
Publicado: (2009)

Compulsive Drumming Induced by Dopamine Agonists in Parkinson’s Disease: Another Aspect of Punding
por: Vitale, Carmine, et al.
Publicado: (2013)

Impact of behavioral side effects on the management of Parkinson patients treated with dopamine agonists
por: Mohammad, Mohammad Edrees, et al.
Publicado: (2021)

No Dopamine Agonist Modulation of Brain [(18)F]FEOBV Binding in Parkinson’s Disease
por: Albin, Roger L., et al.
Publicado: (2022)

Withdrawing and withholding life-sustaining therapies are not the same
por: Levin, Phillip D, et al.
Publicado: (2005)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Dopamine agonists and ischemic complications in Parkinson’s disease: a nested case–control study
por: Arbouw, Maurits E. L., et al.
Publicado: (2011)

Prevalence of hypersexual behavior in Parkinson’s disease patients: Not restricted to males and dopamine agonist use
por: Cooper, Christine A, et al.
Publicado: (2009)

Dopamine-agonist responsive Parkinsonism in a patient with the SANDO syndrome caused by POLG mutation
por: Bandettini di Poggio, Monica, et al.
Publicado: (2013)

Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis
por: Thorlund, Kristian, et al.
Publicado: (2014)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Parkinson disease and Neuroleptic withdrawal
por: Jambunathan, Stephen, et al.
Publicado: (2010)

Dopamine Agonists and Pathologic Behaviors
por: Kelley, Brendan J., et al.
Publicado: (2012)

Dopamine Agonists for Pituitary Adenomas
por: Cooper, Odelia, et al.
Publicado: (2018)

Kratom withdrawal: Discussions and conclusions of a scientific expert forum()
por: Henningfield, Jack E., et al.
Publicado: (2023)

Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
por: Ecker, Daniel, et al.
Publicado: (2009)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Dopamine agonist treatment increases sensitivity to gamble outcomes in the hippocampus in de novo Parkinson’s disease
por: van der Vegt, Joyce P.M., et al.
Publicado: (2020)

Nonconsensual withdrawal of nutrition and hydration in prolonged disorders of consciousness: authoritarianism and trustworthiness in medicine
por: Rady, Mohamed Y, et al.
Publicado: (2014)

Rasagiline Withdrawal Syndrome in Parkinson’s Disease
por: Solla, Paolo, et al.
Publicado: (2022)

Impulse control disorders and dopamine agonists
por: Martins, D., et al.
Publicado: (2021)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
por: Barabash, Nadiya Ye., et al.
Publicado: (2022)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o7j7igba2m6abtcsaseh2mqtsb